Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Sutro goes back to work
The restructured biotech’s new lead project enters phase 1.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Mersana gets its rescue bid
But the Day One deal is still 29% below where the shares stood at the start of this year.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
